Treatment options for advanced or metastatic NSCLC without actionable molecular biomarkers are stratified by the PD-L1 level and include systemic therapy options such as immunotherapy with or without chemotherapy [46]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.